Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology

(2010) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

(2008) Diane Lacaille et al.   ARTHRITIS AND RHEUMATISM

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY